...
首页> 外文期刊>Clinical Neuropsychiatry: Journal Of Treatments Evaluation >SEROTONINERGIC AND DOPAMINERGIC GENES IN BIPOLAR DISORDER AND RESPONSE TO TREATMENTS IN BIPOLAR DEPRESSION
【24h】

SEROTONINERGIC AND DOPAMINERGIC GENES IN BIPOLAR DISORDER AND RESPONSE TO TREATMENTS IN BIPOLAR DEPRESSION

机译:双相障碍中的血清酮能和多巴胺能基因,对双相抑郁症治疗的反应

获取原文

摘要

Inheritable factors are known to play an important role in the risk for Bipolar disorder (BD) as well as response to pharmacological treatment. In the present study, we further investigated four candidate genes for BD and response to pharmacological treatments, in a naturalistic sample of 131 patients and 65 healthy controls. Patients were characterized for socio-demographic and clinical variables, including substance abuse, axis II personality disorders, temperamental traits and social adjustment. Patients meeting criteria for a depressive episode were followed for 6-months of pharmacological treatment (n=92). Polymorphisms within the genes for Serotonin receptor 2A (5HTR2A), trypthophan hydroxylase 1 (TPH1), Dopamine receptor D2 (DRD2) and Dopamine receptor D4 (DRD4), were analyzed for the present study. 5HTR2A, DRD2 and DRD4 variants were not associated to BD, response to treatment and other variables considered in the study. A haplotype in TPH1 (rs I 800532-rs7933505) showed a trend of association with BD, though non-significantly considering correction for multiple testing. Taking into account limitations linked to the small sample size and the naturalistic approach in recruitment and treatment of BD patients, this study does not support an involvement of the genes here considered in BD and medium- term outcome of bipolar depression. Further studies are required to clarify the role of TPHI, particularly of the less investigated rs7933505 variant in BD.
机译:已知可遗传因素在双相障碍(BD)的风险中起重要作用以及对药理学治疗的反应。在本研究中,我们进一步研究了对BD的四种候选基因和对药理治疗的反应,在131名患者和65例健康对照中的自然样品中。患者的特征是社会人口统计学和临床​​变量,包括药物滥用,轴II个性障碍,气质性状和社会调整。遵循抑郁发作标准的患者进行6个月的药理学治疗(n = 92)。对本研究分析了血清素受体2A(5HTR2A),杂霉素羟化酶1(TPH1),多巴胺受体D2(DRD2)和多巴胺受体D4(DRD4)的多态性。 5HTR2A,DRD2和DRD4变体与BD无关,对研究中考虑的治疗和其他变量相关联。 TPH1中的单倍型(RS 800532-RS7933505)显示了与BD相关联的趋势,尽管是非显着考虑多次测试的校正。考虑到与小样本规模相关的限制和BD患者的招生和治疗中的自然主义方法,该研究不支持在BD中考虑的基因和双极抑郁症的中期结果的参与。需要进一步的研究来阐明TPHI的作用,特别是BD中较少研究的RS7933505变体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号